Boston Scientific Shares Fall After Cyberattack Impacts Sales and Earnings Guidance
Boston Scientific (BSX) shares dropped approximately 6% following the company's announcement of reduced fourth-quarter and full-year guidance. The downward revision stems from an eight-day operational disruption caused by a cyberattack, which management estimates cost the company 300 basis points in sales growth and $0.07 in adjusted earnings per share. In its third-quarter results, the medical device maker reported a 1.5% sales increase and $0.73 in adjusted EPS, missing previous guidance of 3% to 5% sales growth and $0.80 to $0.82 in adjusted EPS. CEO Mahoney indicated that recovery will be gradual, projecting 2027 as the trough in the current cycle despite upcoming product innovations and the pending acquisition of Penumbra.
Topics: cyberattack earnings miss medical devices revenue guidance
Read the full article at Motley Fool
Part of the story Boston Scientific Shares Fall After Cyberattack Impacts Sales and Earnings Guidance (2 articles)